{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T09:33:42Z","timestamp":1771493622861,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2012,10,29]],"date-time":"2012-10-29T00:00:00Z","timestamp":1351468800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"},{"start":{"date-parts":[[2012,10,29]],"date-time":"2012-10-29T00:00:00Z","timestamp":1351468800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                        <jats:title>Introduction<\/jats:title>\n                        <jats:p>We identified silent liver fibrosis in patients with rheumatoid arthritis (RA) using transient elastography, and investigated medication that correlated with abnormal liver stiffness measurement (LSM) values.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Methods<\/jats:title>\n                        <jats:p>We consecutively enrolled 105 patients with RA taking methotrexate over 24 weeks with normal liver functions and no history of underlying chronic liver disease. Blood tests were performed, and body mass index and metabolic syndrome were assessed. We checked LSM values, and adopted 5.3 kPa as the cutoff for abnormal LSM values. The cumulative doses of medications including methotrexate, leflunomide, sulfasalazine, hydroxychloroquine, prednisolone, meloxicam, and celecoxib were calculated.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Results<\/jats:title>\n                        <jats:p>The median age of patients (20 men and 85 women) was 52.4 years. The median LSM value was 4.7 kPa and 24 (22.9%) patients had abnormal LSM values. Gamma-glutamyltranspeptidase levels and the cumulative doses of leflunomide and prednisolone significantly correlated with LSM values (<jats:italic>P<\/jats:italic>&lt;0.05). The cumulative dose of leflunomide, but not methotrexate, was significantly higher in patients with abnormal LSM values than that in patients with normal LSM values (<jats:italic>P<\/jats:italic> = 0.008). When RA patients receiving leflunomide plus methotrexate were classified into two groups according to the optimal cutoff cumulative dose of leflunomide (19,170 mg), abnormal LSM values were more frequently identified in patients with high cumulative dose of leflunomide (odds ratio, 12.750; <jats:italic>P<\/jats:italic>&lt;0.001).<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Conclusions<\/jats:title>\n                        <jats:p>The cumulative dose of leflunomide was the only independent predictor of abnormal LSM values in patients with RA who had received methotrexate for more than six months.<\/jats:p>\n                     <\/jats:sec>","DOI":"10.1186\/ar4075","type":"journal-article","created":{"date-parts":[[2012,10,29]],"date-time":"2012-10-29T16:21:00Z","timestamp":1351527660000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Leflunomide increases the risk of silent liver fibrosis in patients with rheumatoid arthritis receiving methotrexate"],"prefix":"10.1186","volume":"14","author":[{"given":"Sang-Won","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hee-Jin","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beom Kyung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwang-Hyub","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soo-Kon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung Up","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-Beom","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,10,29]]},"reference":[{"key":"3814_CR1","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1056\/NEJM200103223441207","volume":"344","author":"EH Choy","year":"2001","unstructured":"Choy EH, Panayi GS: Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med. 2001, 344: 907-916. 10.1056\/NEJM200103223441207.","journal-title":"N Engl J Med"},{"key":"3814_CR2","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1196\/annals.1361.116","volume":"1051","author":"J Zwerina","year":"2005","unstructured":"Zwerina J, Redlich K, Schett G, Smolen JS: Pathogenesis of rheumatoid arthritis: targeting cytokines. Ann NY Acad Sci. 2005, 1051: 716-729. 10.1196\/annals.1361.116.","journal-title":"Ann NY Acad Sci"},{"key":"3814_CR3","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1159\/000289205","volume":"11","author":"PP Sfikakis","year":"2010","unstructured":"Sfikakis PP: The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. Curr Dir Autoimmun. 2010, 11: 180-210.","journal-title":"Curr Dir Autoimmun"},{"key":"3814_CR4","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1002\/art.1780330116","volume":"33","author":"HE Paulus","year":"1990","unstructured":"Paulus HE: The use of combinations of disease-modifying antirheumatic agents in rheumatoid arthritis. Arthritis Rheum. 1990, 33: 113-120. 10.1002\/art.1780330116.","journal-title":"Arthritis Rheum"},{"key":"3814_CR5","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1002\/art.1780371013","volume":"37","author":"ME Weinblatt","year":"1994","unstructured":"Weinblatt ME, Kaplan H, Germain BF, Block S, Solomon SD, Merriman RC, Wolfe F, Wall B, Anderson L, Gall E, Torretti D, Weissman B: Methotrexate in rheumatoid arthritis. A five-year prospective multicenter study. Arthritis Rheum. 1994, 37: 1492-1498. 10.1002\/art.1780371013.","journal-title":"Arthritis Rheum"},{"key":"3814_CR6","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/0049-0172(94)90027-2","volume":"23","author":"A Schnabel","year":"1994","unstructured":"Schnabel A, Gross WL: Low-dose methotrexate in rheumatic diseases-efficacy, side effects, and risk factors for side effects. Semin Arthritis Rheum. 1994, 23: 310-327. 10.1016\/0049-0172(94)90027-2.","journal-title":"Semin Arthritis Rheum"},{"key":"3814_CR7","first-page":"1017","volume":"27","author":"K Visser","year":"2009","unstructured":"Visser K, van der Heijde DM: Risk and management of liver toxicity during methotrexate treatment in rheumatoid and psoriatic arthritis: a systematic review of the literature. Clin Exp Rheumatol. 2009, 27: 1017-1025.","journal-title":"Clin Exp Rheumatol"},{"key":"3814_CR8","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1136\/ard.2008.099861","volume":"68","author":"W Katchamart","year":"2009","unstructured":"Katchamart W, Trudeau J, Phumethum V, Bombardier C: Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2009, 68: 1105-1112. 10.1136\/ard.2008.099861.","journal-title":"Ann Rheum Dis"},{"key":"3814_CR9","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1002\/1529-0131(200011)43:11<2609::AID-ANR32>3.0.CO;2-R","volume":"43","author":"ME Weinblatt","year":"2000","unstructured":"Weinblatt ME, Dixon JA, Falchuk KR: Serious liver disease in a patient receiving methotrexate and leflunomide. Arthritis Rheum. 2000, 43: 2609-2611. 10.1002\/1529-0131(200011)43:11<2609::AID-ANR32>3.0.CO;2-R.","journal-title":"Arthritis Rheum"},{"key":"3814_CR10","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1478-3231.2009.02172.x","volume":"30","author":"SU Kim","year":"2010","unstructured":"Kim SU, Choi GH, Han WK, Kim BK, Park JY, Kim do Y, Choi JS, Yang SC, Choi EH, Ahn SH, Han KH, Chon CY: What are 'true normal' liver stiffness values using FibroScan?: a prospective study in healthy living liver and kidney donors in South Korea. Liver Int. 2010, 30: 268-274. 10.1111\/j.1478-3231.2009.02172.x.","journal-title":"Liver Int"},{"key":"3814_CR11","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1002\/hep.24121","volume":"53","author":"KS Jung","year":"2011","unstructured":"Jung KS, Kim SU, Ahn SH, Park YN, Kim do Y, Park JY, Chon CY, Choi EH, Han KH: Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan). Hepatology. 2011, 53: 885-894. 10.1002\/hep.24121.","journal-title":"Hepatology"},{"key":"3814_CR12","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/j.1365-2036.2010.04353.x","volume":"32","author":"SU Kim","year":"2010","unstructured":"Kim SU, Seo YS, Cheong JY, Kim MY, Kim JK, Um SH, Cho SW, Paik SK, Lee KS, Han KH, Ahn SH: Factors that affect the diagnostic accuracy of liver fibrosis measurement by Fibroscan in patients with chronic hepatitis B. Aliment Pharmacol Ther. 2010, 32: 498-505. 10.1111\/j.1365-2036.2010.04353.x.","journal-title":"Aliment Pharmacol Ther"},{"key":"3814_CR13","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.jbspin.2010.02.024","volume":"77","author":"SH Park","year":"2010","unstructured":"Park SH, Choe JY, Kim SK: Assessment of liver fibrosis by transient elastography in rheumatoid arthritis patients treated with methotrexate. Joint Bone Spine. 2010, 77: 588-592. 10.1016\/j.jbspin.2010.02.024.","journal-title":"Joint Bone Spine"},{"key":"3814_CR14","doi-asserted-by":"publisher","first-page":"575","DOI":"10.3109\/00365521.2011.647412","volume":"47","author":"A Barbero-Villares","year":"2012","unstructured":"Barbero-Villares A, Mendoza Jim\u00e9nez-Ridruejo J, Taxonera C, L\u00f3pez-Sanrom\u00e1n A, Pajares R, Bermejo F, P\u00e9rez-Calle JL, Mendoza JL, Algaba A, Moreno-Otero R, Mat\u00e9 J, Gisbert JP, Madrid Group for the Study of Inflammatory Bowel Disease ENICMAD: Evaluation of liver fibrosis by transient elastography (Fibroscan\u00ae) in patients with inflammatory bowel disease treated with methotrexate: a multicentric trial. Scand J Gastroenterol. 2012, 47: 575-579. 10.3109\/00365521.2011.647412.","journal-title":"Scand J Gastroenterol"},{"key":"3814_CR15","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.dld.2011.08.013","volume":"44","author":"U Arena","year":"2012","unstructured":"Arena U, Stasi C, Mannoni A, Benucci M, Maddali-Bongi S, Cammelli D, Assarat A, Marra F, Pinzani M: Liver stiffness correlates with methotrexate cumulative dose in patients with rheumatoid arthritis. Dig Liver Dis. 2012, 44: 149-153. 10.1016\/j.dld.2011.08.013.","journal-title":"Dig Liver Dis"},{"key":"3814_CR16","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988, 31: 315-324. 10.1002\/art.1780310302.","journal-title":"Arthritis Rheum"},{"key":"3814_CR17","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/S0140-6736(05)67402-8","volume":"366","author":"KG Alberti","year":"2005","unstructured":"Alberti KG, Zimmet P, Shaw J, IDF Epidemiology Task Force Consensus Group: The metabolic syndrome-a new worldwide definition. Lancet. 2005, 366: 1059-1062. 10.1016\/S0140-6736(05)67402-8.","journal-title":"Lancet"},{"key":"3814_CR18","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1093\/rheumatology\/36.3.338","volume":"36","author":"C Beyeler","year":"1997","unstructured":"Beyeler C, Reichen J, Thomann SR, Lauterburg BH, Gerber NJ: Quantitative liver function in patients with rheumatoid arthritis treated with low-dose methotrexate: a longitudinal study. Br J Rheumatol. 1997, 36: 338-344. 10.1093\/rheumatology\/36.3.338.","journal-title":"Br J Rheumatol"},{"key":"3814_CR19","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1080\/030097402320817040","volume":"31","author":"S Ros","year":"2002","unstructured":"Ros S, Juanola X, Condom E, Ca\u00f1as C, Riera J, Guardiola J, Del Blanco J, Rebasa P, Valverde J, Roig-Escofet O: Light and electron microscopic analysis of liver biopsy samples from rheumatoid arthritis patients receiving long-term methotrexate therapy. Scand J Rheumatol. 2002, 31: 330-336. 10.1080\/030097402320817040.","journal-title":"Scand J Rheumatol"},{"key":"3814_CR20","first-page":"229","volume":"19","author":"CA Phillips","year":"1992","unstructured":"Phillips CA, Cera PJ, Mangan TF, Newman ED: Clinical liver disease in patients with rheumatoid arthritis taking methotrexate. J Rheumatol. 1992, 19: 229-233.","journal-title":"J Rheumatol"},{"key":"3814_CR21","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1002\/art.1780360307","volume":"36","author":"AM Walker","year":"1993","unstructured":"Walker AM, Funch D, Dreyer NA, Tolman KG, Kremer JM, Alarc\u00f3n GS, Lee RG, Weinblatt ME: Determinants of serious liver disease among patients receiving low-dose methotrexate for rheumatoid arthritis. Arthritis Rheum. 1993, 36: 329-335. 10.1002\/art.1780360307.","journal-title":"Arthritis Rheum"},{"key":"3814_CR22","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s100510070069","volume":"18","author":"MY Mok","year":"2000","unstructured":"Mok MY, Ng WL, Yuen MF, Wong RW, Lau CS: Safety of disease modifying anti-rheumatic agents in rheumatoid arthritis patients with chronic viral hepatitis. Clin Exp Rheumatol. 2000, 18: 363-368. 10.1007\/s100510070069.","journal-title":"Clin Exp Rheumatol"},{"key":"3814_CR23","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1097\/BOR.0b013e328344fddb","volume":"23","author":"F Behrens","year":"2011","unstructured":"Behrens F, Koehm M, Burkhardt H: Update 2011: leflunomide in rheumatoid arthritis - strengths and weaknesses. Curr Opin Rheumatol. 2011, 23: 282-287. 10.1097\/BOR.0b013e328344fddb.","journal-title":"Curr Opin Rheumatol"},{"key":"3814_CR24","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.2165\/11316650-000000000-00000","volume":"32","author":"N Alcorn","year":"2009","unstructured":"Alcorn N, Saunders S, Madhok R: Benefit-risk assessment of leflunomide: an appraisal of leflunomide in rheumatoid arthritis 10 years after licensing. Drug Saf. 2009, 32: 1123-1134. 10.2165\/11316650-000000000-00000.","journal-title":"Drug Saf"},{"key":"3814_CR25","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1002\/art.22666","volume":"56","author":"JH Ju","year":"2007","unstructured":"Ju JH, Kim SI, Lee JH, Lee SI, Yoo WH, Choe JY, Chung SH, Lee J, Lee YH, Lee SS, Yoon HJ, Yoon CH, Kim HY, Park SH: Risk of interstitial lung disease associated with leflunomide treatment in Korean patients with rheumatoid arthritis. Arthritis Rheum. 2007, 56: 2094-2096. 10.1002\/art.22666.","journal-title":"Arthritis Rheum"},{"key":"3814_CR26","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1053\/j.gastro.2008.01.034","volume":"134","author":"M Friedrich-Rust","year":"2008","unstructured":"Friedrich-Rust M, Ong MF, Martens S, Sarrazin C, Bojunga J, Zeuzem S, Herrmann E: Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology. 2008, 134: 960-974. 10.1053\/j.gastro.2008.01.034.","journal-title":"Gastroenterology"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/ar4075.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/ar4075\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/ar4075.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T10:46:45Z","timestamp":1728384405000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/ar4075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,29]]},"references-count":26,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2012,10]]}},"alternative-id":["3814"],"URL":"https:\/\/doi.org\/10.1186\/ar4075","relation":{},"ISSN":["1478-6354"],"issn-type":[{"value":"1478-6354","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10,29]]},"assertion":[{"value":"23 May 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2012","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2012","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2012","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"R232"}}